TIDMSCLP
Scancell Holdings Plc
10 May 2019
10 May 2019
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell Establishes Clinical Advisory Board and Provides Update
on Modi-1 Progress
Appoints six world class clinical oncologists to guide the
Moditope(R) clinical development strategy
Modi-1 manufacturing and toxicity testing underway to support
anticipated start of Phase 1/2 study in
Q1 2020
Scancell Holdings plc, the developer of novel immunotherapies
for the treatment of cancer, today announces that it has appointed
six world-leading clinicians to establish its Clinical Advisory
Board ("CAB"). The Board will be chaired by Professor Robert
Coleman and will provide strategic guidance and support as the
Company prepares for its lead Moditope(R) candidate, Modi-1, to
enter the clinic in Q1 2020 in multiple tumour types, including
head and neck, breast and ovarian cancer.
The CAB comprises: Professor Robert Coleman, Emeritus Professor
of Medical Oncology at Weston Park Hospital and the University of
Sheffield; Professor Christian Ottensmeier, Professor of
Experimental Cancer Medicine at the University of Southampton;
Professor Poulam Patel, Professor of Clinical Oncology at the
University of Nottingham and Honorary Consultant Medical Oncologist
at the Nottingham University Hospitals NHS Trust; Professor Iain
McNeish, Professor of Oncology and Head of the Division of Cancer
within the Department of Surgery and Cancer, Imperial College
London; Professor David Miles, Lead Clinician for breast cancer at
Mount Vernon Cancer Centre; and Professor Stephen Chan, Director of
Clinical Trials in Breast Cancer and Gynaecological Cancer at
Nottingham University Hospital.
The Company also provides an update on progress towards
initiating the Modi-1 Phase 1/2 clinical trial.
-- Good Manufacturing Practice (GMP) synthesis of the bulk
Modi-1 peptide conjugates is underway at the PolyPeptide Group's
facilities in The Netherlands.
-- The Company signed an agreement at the end of April 2019 with
AMRI (Glasgow, UK), a global contract and manufacturing
organisation, to formulate, manufacture and package the Modi-1 GMP
final product for clinical testing.
-- The preclinical toxicity testing programme required prior to
the start of the clinical trial commenced in April 2019 and is
anticipated to be completed during H2 2019.
Scancell's Moditope(R) platform acts by stimulating the
production of CD4 T cells using citrullinated tumour-associated
peptide epitopes. This technology overcomes the immune suppression
induced by tumours themselves, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Previous pre-clinical data demonstrated that
conjugation of the Modi-1 peptides to Amplivant(R) enhances
anti-tumour immune responses 10-100 fold and resulted in highly
efficient tumour eradication, including protection against tumour
recurrence.
Dr Cliff Holloway, Chief Executive Officer, Scancell, said:
"We are delighted to welcome all six experienced clinicians to
our Clinical Advisory Board and the creation of this Board is part
of our wider strategy to fully develop and deliver the full
potential of the Moditope(R) platform across multiple tumour types.
The initial focus of the Board will be to inform the clinical
strategy for the planned Modi-1 clinical trial and to ensure the
best possible outcome in several solid tumour indications,
including ovarian cancer, head and neck cancer, and triple negative
breast cancer. Significant progress has been made towards
completing the GMP manufacture of the Modi-1 product and the
preclinical testing required prior to the anticipated start of the
trial early in 2020."
Chair of the Clinical Advisory Board, Professor Robert Coleman
said:
"I am pleased to be working alongside Christian, Poulam, Iain,
David and Stephen, who collectively have long, established track
records in scientific and clinical research in oncology. I am
looking forward to chairing the Clinical Advisory Board and working
closely with my Board colleagues and the Scancell team to realise
the full potential of Scancell's Moditope(R) immunotherapy platform
through future clinical development."
Detailed biographies of the Clinical Advisory Board are provided
below and will be available at: www.scancell.co.uk
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
For further details, please see our website:
www.scancell.co.uk
Scancell Clinical Advisory Board
Chairman, Professor Robert Coleman MBBS, MD, FRCP, FRCPE
Robert Coleman is Emeritus Professor of Medical Oncology at
Weston Park Hospital and the University of Sheffield. He graduated
in medicine from Kings College Hospital Medical School and trained
in London and Edinburgh before moving to Sheffield where he was
instrumental in developing clinical cancer research in the city and
establishing an internationally respected bone oncology research
team. Professor Coleman held many leadership roles before his
recent retirement from the University. He has written more than 450
scientific articles and 60 book chapters, is a past-president of
the Cancer and Bone Society and was a trustee for Breast Cancer
Now, the largest breast cancer research charity in the UK from
2010-2018. Currently he is a trustee at St Luke's Hospice in
Sheffield and the Weston Park Cancer Charity. Since 2014 he has
been a part-time Medical Director for the global independent
medical education provider, prIME Oncology(TM) developing and
delivering both live and on-line educational programmes for
oncologists and other providers of cancer care.
Professor Christian Ottensmeier MD, PhD, FRCP
Christian Ottensmeier is Professor of Experimental Cancer
Medicine at the University of Southampton. He graduated in Münster,
Germany and began his specialist training there. After a 3-year
training fellowship in the Dana Farber Cancer Institute in Boston,
Massachusetts, he moved to Southampton where he leads the
Experimental Cancer Medicine Centre. He has been a consultant in
medical oncology since 2000. Clinically his interests are thoracic
malignancies, head & neck cancer and melanoma, and he has
co-developed a number of national NCRI studies in lung cancer. He
is at the forefront of research into cancer vaccines and manages a
broad and active clinical trials portfolio, including lung cancer
and melanoma.
Professor Poulam Patel MD, PhD, MBBS, FRCP
Poulam Patel is Professor of Clinical Oncology at the University
of Nottingham and Honorary Consultant Medical Oncologist at the
Nottingham University Hospitals NHS Trust. He combines laboratory
research with clinical practice focussing on the development of new
treatments for several cancer types including malignant melanoma
and renal cancer. He has been principal investigator for many
trials of novel therapies, including Scancell's Phase 1/2 clinical
trial of SCIB1-001 in melanoma patients. Professor Patel is
currently the Chairman of the UK National Cancer Research
Institute's Skin Cancer Clinical Studies Group, the
multidisciplinary committee charged with developing the national
trials portfolio for skin cancer. He has previously been a National
Cancer Specialty lead of the NIHR Clinical Research Network, the
clinical trials arm of the NHS, and Chairman of the EORTC Melanoma
Group, one of the world's largest international melanoma clinical
trials networks.
Professor Iain McNeish MD, PhD, FRCP
Iain McNeish is Professor of Oncology and Head of the Division
of Cancer within the Department of Surgery and Cancer, Imperial
College London. He is also the Director of the Ovarian Cancer
Action Research Centre and Cancer theme lead in the Imperial NIHR
Biomedical Research Centre (BRC). Externally, he is Chair of the
NCRI Gynaecological Clinical Studies Group. His research focuses on
ovarian cancer, specifically developing improved therapies through
improved understanding of disease biology. He co-leads the BriTROC
translational research collaborative and holds a programme grant
from Cancer Research UK investigating copy number alterations in
ovarian high-grade serous carcinoma as a possible prognostic and
predictive biomarker.
Professor David Miles MB, BS, BSc, FRCP, MD
David Miles is a consultant oncologist who specialises in breast
cancer treatment, with over 20 years' experience in the field.
Professor Miles was head of the Breast Cancer Biology Group at
Guy's and St Thomas's, and more recently became Lead Clinician for
breast cancer at Mount Vernon Cancer Centre. Professor Miles is the
Global Principal Investigator in clinical trials of biological
therapies in the treatment of breast cancer and serves on a number
of clinical trial steering and independent data monitoring
committees for studies of novel therapies for the treatment of
breast and other cancers. Professor Miles also advises the National
Institute for Health and Clinical Excellence (NICE) on the adoption
of new drugs being considered for breast cancer.
Professor Stephen Chan DM, FRCP, FRCR
Stephen Chan is the Director of Clinical Trials in Breast Cancer
and Gynaecological Cancer at Nottingham University Hospital. For
over two decades he has been at the forefront of researching and
treating breast and gynaecological cancer, focussing on specialist
treatment areas including chemotherapy, radiotherapy and targeted
therapies. Professor Chan qualified at Nottingham University
Medical School followed by further research and training at Oxford,
Cambridge and London hospitals and universities. Professor Chan
leads the Nottingham Personalised Therapy Oncology Research Group
and the Breast & Gynaecological Clinical Trial Group with a
particular interest in identifying new cancer genes and tests to
select the best treatment for individual patients.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAZMGGKLLDGLZM
(END) Dow Jones Newswires
May 10, 2019 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024